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Abstract
Objective: To determine whether HPV L1 gene methylation can be
used in triage of precancerous cervical lesions. The main objective is
to determine the genotype of HPV in cervical precancerous lesions
and to determine the percentage, the sensitivity, specificity, positive
predictive value, negative predictive value, and likelihood ratio of
DNA HPV L1 methylation in precancerous cervical lesions.
Methods: A number of 57 samples of paraffin blocks (FFPE) from
precancerous lesions and cervical cancer biopsies in the Department
of Pathology Faculty of Medicine-Cipto Mangunkusumo General
Hospital that had been re-evaluated by the pathologist, underwent
extraction of HPV DNA. The genotypes of HPV DNA were examined
using primers GP5 / 6 and specific HPV 16, HPV 18 and HPV 52
probes and analyzed by real time PCR. Sequencing was performed
on samples with unknown HPV DNA type that were detected using
the specific probes to determine the type of HPV. Bisulfite conver-
sion procedure was then performed for the samples that met the in-
clusion criteria.
Results: There were 30 samples (52.6%) with CIN 1, 12 samples
(21.1%) CIN 2, 9 samples (15.8%) CIN 3 and 6 samples (10.5%) of
cervical cancer. Most of the samples were 36-45 years (35.1%). Of
the total 57 samples, 55 samples were successfully extracted and de-
termined the DNA genotyping of HPV (96.5%). HPV 16 infections
both in the form of single or multiple was found to be 76.36%. The
samples were mostly dominated by co-infection of HPV16 and 18
(49.1%) followed by HPV 16 (24.6%) and HPV 18 (14.0%). Based
on the sequencing results there were other types of high risk HPV
infection found: HPV 33, HPV 35, HPV 58 and also undeterminate
risk HPV 53 and low risk HPV 54. After several procedures of
optimization for methylation examination of HPV DNA L1 there was
thin band found in electrophoresis procedure in 8 of 42 samples
(19%) of HPV 16 after bisulfite conversion but once it was purified
there weren’t any band found so we can not proceed to the stage
sequencing. Until now we are still in the stage of optimizing the
methylation procedure.
Conclusion: HPV 16 infection were most commonly found in the
form of single or multiple. Co-infection of HPV 16 and 18 were
found in the majority of the samples. There were no significant
correlation between HPV type and the severity of cervical lesions.
Until now, the examination of DNA methylation HPV L1 already
obtained eight samples of HPV 16 with a thin band on electro-
phoresis but the result could not be concluded because it is still in
the process of optimization.
[Indones J Obstet Gynecol 2017; 5-2: 120-126]
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Abstrak
Tujuan: Untuk mengetahui apakah metilasi HPV DNA dapat
digunakan dalam triage lesi prakanker serviks. Tujuan khusus-nya adalah untuk mengetahui genotipe HPV pada lesi prakanker
serviks dan untuk mengetahui persentase, sensitivitas, spesifisi-
tas, nilai duga positif, nilai duga negatif, dan likelihood ratiometilasi HPV DNA L1 pada lesi prakanker serviks.
Metode: Sejumlah 57 sampel paraffin block (FFPE) hasil biopsi lesiprakanker dan kanker serviks di Departemen Patologi Anatomi FKUI-
RSCM dilakukan ekstraksi DNA HPV. Dilanjutkan dengan pemerik-saan genotipe DNA HPV menggunakan primer GP5/6 dan probe
khusus HPV 16, HPV 18 dan HPV 52 yang kemudian dianalisis dengan
real time PCR. Dilakukan sequencing pada sampel dengan DNA HPVyang tidak dikenal dengan probe spesifik untuk mengetahui tipe HPV.
Selanjutnya dilakukan prosedur konversi bisulfit untuk sampel yang
memenuhi kriteria inklusi.
Hasil: Terdapat 30 sampel (52,6%) NIS 1, 12 sampel (21,1%) NIS 2,9 sampel (15,8%) NIS 3 dan 6 sampel (10,5%) kanker serviks.
Kelompok usia terbanyak adalah 36-45 tahun (35,1%). Dari total 57
sampel terdapat 55 sampel yang berhasil diekstraksi dan diperiksagenotyping DNA HPV (96,5%). Infeksi HPV 16 baik dalam bentuk
tunggal maupun multipel ditemukan sebesar 76,36%. Genotipe HPV
yang terbanyak ditemukan adalah ko-infeksi HPV tipe 16 & 18(49,1%) diikuti dengan tipe 16 (24,6%) dan tipe 18 (14,0%). Ber-
dasarkan hasil sequencing ditemukan infeksi high risk HPV 33, HPV35, HPV 58, undeterminate risk HPV 53 dan low risk HPV 54 pada
masing-masing 1 sampel. Setelah dilakukan beberapa prosedur
tahap anoptimasi untuk pemeriksaan metilasi HPV DNA L1,didapatkan band yang tipis pada 8 dari 42 sampel (19%) HPV 16
hasil konversi bisulfit tetapi setelah dipurifikasi masih belum
didapatkan adanya band pada proses elektro foresis sehinggabelum dapat dilanjutkan ke tahap sequencing. Saat ini masih
dilakukan proses optimasi untuk pemeriksaan metilasi HPVDNA L1.
Kesimpulan: Genotipe DNA HPV yang paling banyak ditemukan baikdalam bentuk tunggal maupun multipel adalah HPV 16. Infeksi multi-
pel (ko-infeksi) HPV 16 dan 18 ditemukan pada sebagian besar sampel
penelitian. Tidak didapatkan hubungan bermakna antara tipe HPVdan derajat beratnya lesi serviks. Hingga saat ini pada pemeriksaan
metilasi HPV DNA L1 sudah didapatkan 8 sampel HPV 16 denganband yang tipis pada elektro foresis namun belum dapat disimpulkan
karena masih dalam proses optimasi.
[Maj Obstet Ginekol Indones 2017; 5-2: 120-126]
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INTRODUCTION
Cervical cancer is still a burden for women around
the world. It is the third most common cancer
among, with an estimated 528,000 new cases and
35,673 deaths in 2012. Worldwide, cervical cancer
mortality rates are substantially lower than the
incidence of mortality. The incidence ratio was
50.3%. Most cases are squamous cell carcinoma,
followed by adenocarcinoma.1,2
In Indonesia, cervical cancer ranks as the second
most common female cancer. There are approxi-
mately 20,928 new cases of cervical cancer
annually in Indonesia.1,2 Cervical cancer is about
75% of gynecological cancer in Indonesia. It is
mostly diagnosed at later stages.3 Throughout
2005-2010 at Dr. Cipto Mangunkusumo National
General Hospital (RSCM), there were 2,298 cervical
cancer cases and 66.4% were diagnosed at an
advanced stage, generally stadium IIIB.4 In 2013,
according to a report INASGO there were 823 new
cases in RSCM.5
Human papilloma virus (HPV) which derived
from the genus Alphapapillomavirus is the most
frequent cause of sexually transmitted infection
most frequently worldwide with a broad spectrum
of benign and malignant neoplasms.6 HPV is the
cause of 99.7% cervical cancer.7
Cervical cancer, precancer lesion and non-
neoplastic HPV infection such as atypical cells of
undetermined significance (ASCUS) and cervical
intraepithelial neoplasia (CIN) are diagnosed using
cytology examination (Papanicolau test, Pap test),
colposcopy and histology examination of tissue
biopsy. Methods of screening with cytology (Pap
smear) has sensitivity (51-86%) with a high false
negative rate (15-45%).8 Cytological examination
can not predict which ones are at risk of becoming
malignant, and which are not.
High Risk-HPV DNA detection has become a
powerful criteria to improve the sensitivity of
screening for cervical cancer. HR-HPV DNA test has
a high sensitivity (88-98%) higher than Pap smear
(51-86%), yet with lower specificity (83-94%)
compared to Pap smear (92-99%).11 However,
since most women who are infected with HPV
during their lifetime (> 80%) far exceeded the
incidence of cervical cancer (1%) and because the
value of HPV DNA testing positive more often
indicate a transient infection rather than a
development of cervical cancer, the diagnosis of
HPV DNA alone is not enough to distinguish
benign infections that require intensive treatment.
Although more sensitive than cytology, specificity
and positive predictive value (PPV) HR-HPV DNA
were low compared with cytology. Combined Pap
and HPV testing has a sensitivity and specificity
values higher with a very high negative predictive
value (99-100%) to strengthen the screening of
cervical cancer.8 But the positive predictive value
for detection of precancerous lesions is still low
and can not differentiate HPV infections will
regress with who will experience progression to
cancer.
Treatment for abnormal screening tests includes
colposcopy vs close-surveillance. However, HPV
DNA positive specificity is not sufficient to dis-
tinguish precancerous lesions associated with HPV
(CIN2 +) and the transients are clinically a benign
infection. Colposcopy referral rates were found to
be higher after skrining.9 An unneeded colposcopy
examination, can lead to over diagnosis CIN (mis-
classification) and over treatment. Therefore, a
diagnostic test that can differentiate between
women who are infected with HR-HPV is transient
with risk of progression is necessary.10-12
In preventing excessive procedures in patients
with abnormal Pap smears who are not at risk for
cervical cancer, tests that are sensitive and specific
in detecting high-risk patients are required.6,13-15
HPV DNA methylation has emerged as a
promising biomarker for diagnosis and prognosis
of cervical cancer. Some studies show that women
with HPV infection, methylation levels increased
slowly with increasing duration of persistence of
HPV and more increased with the diagnosis of
cervical cancer. There is an increasing trend of HPV
DNA methylation, especially in L1 and L2 genes in
conjunction with the progressivity disease. DNA
methylation changes the transcriptional regulation
of HPV because of the repression of the expression
of cellular genes and viruses may occur with the
addition of a methyl group to the residue cytosin.
The occurrence of HPV DNA methylation,
especially in the L1 and L2 genes will prevent the
transcription L1 and L2 with the result of no
expression of L1 and L2 which are the components
of HPV capsid. The absence of capsid protein L1,
as antigen that can be fully accessible during the
early stages of lesions intraepithelial squamous
lead to circumstances in which the virus can evade
the immune system thus the infection will be
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retained causing dysplasia which is not recognized
by the immune system, then it will proceed further
on the transformation malignant.6,13,14,16-19
This opens up the possibility to predict which
woman has the chance of disease progression into
cervical cancer. Thus, HPV DNA methylation can be
considered as a potential biomarker in the triage
of patients with cervical cancer risk.
This study is conducted to determine whether
HPV DNA methylation can be used in triage of
cervical precancerous lesions or not. The main
objective is to determine the genotype of HPV in
cervical precancerous lesions and to determine the
percentage, the sensitivity, specificity, positive
predictive value, negative predictive value, and
likelihood ratio of HPV L1 gene methylation in
precancerous cervical lesions. By knowing the
correlation of HPV L1 gene methylation in
precancerous cervical lesions, it is expected that
this examination can be a triage tool to help
identify patients with HPV positive who would
undergo regression and those at risk of pro-
gression into cervical cancer.
METHODS
A cross sectional study design was used to deter-
mine the genotype of HPV, assess the sensitivity,
specificity, positive predictive value, negative pre-
dictive value, and the like hood ratio of HPV DNA
L1 methylation in precancerous lesions of the
cervix.
The study was conducted at the Division of
Gynecologic Oncology, Department of Obstetrics
and Gynecology, Faculty of Medicine, Universitas
Indonesia - Dr. Cipto Mangunkusumo Hospital, the
samples were from the paraffin block bank at the
Department of Pathology Anatomy, Faculty of
Medicine, Universitas Indonesia - Dr. Cipto
Mangunkusumo Hospital and examined in the
research and esoteric laboratory Prodia.
The samples were obtained from tha paraffin
blocks of tissue biopsies from patients with
precancerous lesions and cervical cancer of
the Department of Pathology Anatomy. Slides of
precancerous lesions and cervical cancer to be
sampled underwent re-evaluation by the Patho-
logist. Samples were taken from formalin fixed
paraffin embedded tissue (FFPE) biopsy of cer-
vical precancerous and cervical cancer lesions
from Department of Pathology Anatomy. For
each sample taken 5 slides of FFPE were obtained.
Samples along with the examination request form
were then sent to research and esoteric laboratory
Prodia. HPV DNA was extracted from formalin-
fixed tissue Paraffin Embedded (FFPE) biopsy of
the cervix. Genotyping of HPV DNA types (HPV
16, 18 and 52) was performed before proceeding
to the examination DNA methylation in genes L1
with Bisulfite sequencing.
RESULTS
The study was conducted at the Division of
Gynecology Oncology, Department of Obstetrics
and Gynecology, Faculty of Medicine, Universitas
Indonesia - RSCM in January-September 2016 and
in the Laboratory of Clinical Research & Esoteric
Prodia. Samples were taken from the paraffin block
biopsies of precancerous lesions and cervical
cancer in the Department of Anatomical Pathology,
Faculty of Medicine, Universitas Indonesia-RSCM.
Samples were re-evaluated by the Pathologist to
ensure the validity of the sample met the criteria
of precancerous lesions and cervical cancer. For
uniformity of precancerous cervical lesions
samples taken were sampled with pure CIN 1, CIN
2, and CIN 3 lesions. Histopathologic type of cer-
vical cancer samples was squamous cell carcinoma
of the cervix. There were 57 sample of precan-
cerous lesions and cervical cancer included in this
study.
Characteristics of subjects
The mean age of study subjects was 44 years old.
There were 30 samples (52.6%) with CIN 1 lesion,
12 samples (21.1%) CIN 2, 9 samples (15.8%) CIN
3, and 6 samples (10.5%) of cervical cancer.
In type 1 CIN lesions, the largest age group as
26-35 years old (10%). In CIN 2, the age group
26-35 years old and 36-45 years old respectively
occupies 41.7%. For CIN 3 age group 36-45 years
old and 46-55 years old respectively gained 33.3%.
In cervical cancer was found most in the age group
of 36-45 years old (50%). There was no significant
relationship between the age groups with the
degree of lesion (p = 0.525).
Genotyping HPV
Of the total 57 samples there were 55 samples
successfully extracted and detected its HPV DNA
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genotype (96.5%). Based on Table 1, most of the
samples were co-infected with HPV type 16 and
18 in 28 samples (49.1%) followed by type 16
in 14 samples (24.6%) and type 18 in 8 samples
(14.0%).
There were 5 samples that are not detected by
the HPV 16, 18 and 52 probe, sequencing was then
performed to determine the type of HPV. Based on
the results of sequencing there were 1 sample of
(1.8%) HPV 33; 1 sample (1.8%) HPV 35; 1 sample
(1.8%) HPV 58; 2 samples were not included in the
group of high risk HPV: HPV 53 (1.8%) with
undeterminate risk and HPV 54 (1.8%) with a low
risk potential. HPV type 52 was not found in this
study. There are two samples that cannot be
amplified in CIN 2 and CIN 3. HPV 16 infections
both in the form of single or multiple discovered
by 76.36% of the total sample were infected with
HPV.
In CIN 1 (56.7%) and in CIN 3 (75%), coinfection
of HPV 16 and 18 were mostly found In CIN 2, HPV
16 (54.5%) was the most. In cervical cancer, single
HPV infection of 18 and co-infection of HPV 16 and
18 were highest (33.3%). 
In CIN 1 there is one sample with HPV 35
infection (3.3%) and one sample of single HPV
low risk HPV 54 (3.3%) and 1 sample undeter-
minate risk HPV 53 (3.3%) infection.
In CIN 3 there were two samples with single
infection HPV; HPV 16 (12.5%) and HPV 58
(12.5%). There was no significant relationship
between the types of HPV with the degree of
lesion (p = 0.181).
A total of 55 samples were successfully
amplified and detected its HPV typing, but the
inclusion criteria for methylation are those with
HPV 16, HPV 18 either as a single infection or
multiple infection (co-infection of HPV 16 and 18)
and HPV 52. There was no HPV 52 found in this
study. Therefore, 50 samples were then included
for the examination of L1 gene HPV DNA
methylation.
HPV Methylation
Bisulfite conversion procedure was performed
according to existing protocols followed by
methylation PCR procedures to amplify the HPV
DNA bisulfite conversion results. The primers used
were special primer for HPV16 FP, RP HPV16,
HPV18 and HPV18 FP RP, Integrated DNA
Technology.20-22 The next procedure was the
detection by gel electrophoresis. After several
stages of optimization procedures, there were thin
band in 8 of 42 samples (19%) of HPV 16 after
bisulfite conversion. Six of them were CIN 1,
1 sample CIN 2 and 1 sample of cervical cancer.
However, the samples were polluted with dimers,
so the procedure was followed by purification of
the samples. After PCR was performed on the
purified samples there were no band found on the
electrophoresis examination, thus we can not
proceed to sequencing. Optimization of HPV 16 and
HPV 18 samples are still in progress up currently.
Table 1. HPV Genotyping based on the Histopathology
Genotype
Histopathology
CIN 1 CIN 2 CIN 3 Cervical Cancer Total
HPV 16 6 (20%) 6 (54.5%) 1 (12.5%) 1 (16.7%) 14 (25.5%)
HPV 18 4 (13.3%) 2 (18.2%) 0 (0.0%) 2 (33.3%) 8 (14.5%)
HPV 16 & 18 17 (56.7%) 3 (27.3%) 6 (75.0%) 2 (33.3%) 28 (50.9%)
HPV 33 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (16.7%) 1 (1.8%)
HPV 35 1 (3.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.8%)
HPV 58 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (1.8%)
HPV 53 1 (3.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.8%)
HPV 54 1 (3.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.8%)
Total 30 (100%) 11 (100%) 8 (100%) 6 (100%) 55 (100%)
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DISCUSSION
In this study, we obtained 57 samples of paraffin
blocks of precancerous lesions and cervical cancer.
After extraction of HPV DNA, 55 samples (96.5%)
were successfully amplified and performed geno-
typing. This is a success of its own because the
method of detection of HPV in tissue samples is
more difficult to do than sitology specimens. This
due to formalin fixation which can cause DNA
damage, including cross-linking and fragmentasi.23
HPV DNA genotyping was done by using primers
GP5 + / GP6 + with specific probes HPV 16, HPV
18, and HPV 52. The three HPV typeswere chosen
based on the three types of HPV with the highest
prevalence in Indonesia on previous studies.24-27
In a study involving 11 case control studies from
nine countries conducted by Munoz N., et al HPV
infection was detected in 90.7% of cases using the
primers MY09 / MY011. In this study we used the
primers GP5 + / 6 +, and HPV DNA was detected
in 96.6% of patients.28
In this study, HPV 16 infection was found the
most, 76.36% of the total 55 samples, either in the
form of single or multiple infections. Most of the
samples were infected with multiple HPV infection
16 and 1849.1%, followed by a single infection of
HPV 16 (24%) and single infection with HPV 18
(14%).
In a study in Jakarta by de Boer et al, it is
reported that HPV 16 (35%) and HPV 18 (28%)
were the most common types of cervical cancer.26
This is some what different from the study in
Indonesia conducted Bosch et al in 1995 with the
highest prevalence of HPV is HPV 18 (48.9%) in 45
samples followed by HPV 16 as much as 31.9%.29
One interesting thing in this study is there was
no of HPV 52 on the overall samples examined.
This is different to that obtained in previous
studies in Indonesia.
The study conducted by the JNI Vet et al in the
three regions in Indonesia (Jakarta, Tasikmalaya
and Bali) of 2686 samples most were infected with
HPV 52 (23.2%), HPV 16 (18%), HPV 18 (16.1%)
and HPV 39 (11.8%). Multiple infection was found
in 20.7% of samples.25
A study by Schellekens et al in Jakarta on 74
cervical cancer specimens obtained three types of
HPV mostly infected with HPV 16 (44%), HPV 18
(39%) and HPV 52 (14%). Multiple HPV infections
were present in 14.1% of the total HPV positive
samples.24 While the study conducted in Singapore
by Sahiratmadja et al in 96 cases of cervical cancer
90% samples were infected with multiple HPV 16
infections both with HPV 18, HPV 45 and HPV 52.
Only three samples were infected with single
HPV 16.27
Most of the samples in this study are co-infected
with HPV 16 and 18. This is in line with the cohort
by Siddiqa A., et al in Pakistan with samples FFPE
tissue biopsies using the primers GP5 + / GP6 +,
which are also used in this study, and they found
HPV positive in 94, 81% of the samples. Infection
with HPV 16 in the form of single or co-infection
was found in 64.94% of the samples and HPV 18
was found in 66.23% of the samples. Single
infection with HPV 16 was found in 24.68% of
the sample and a single infection of HPV in
25.97% of the samples. In this study, 40.26% of
samples found positive co-infection with HPV 16
and HPV 18. This is significantly higher than the
incidence of co-infection with HPV 16/18 found
previously in Pakistan (<2%), in Saudi Arabia
(6.7%) and Indonesia (4.1%).24,30-32
In this study, we obtained more multiple HPV
infection (co-infection with HPV 16 and 18)
compared to with single infection. However, one
thing to note, in this study we only use three
probes specifically for HPV 16, 18 and 52 so co-
infection of HPV 16 or 18 other HPV types could
possibly present but can not be detected by the
probes.
In this study, co-infection of HPV 16 and 17 were
mostly found in CIN 1 (56.7%) and CIN 3 (75%).
In CIN 2 lesions, HPV 16 (54.5%) was mostly
found. In cervical cancer, single HPV 18 infection
and co-infection of HPV 16 and 18 were the most
found (33.3%). In addition to HPV 16 and 18, in
CIN 1 lesion there is one sample with HPV 35
infection (3.3%) and 2 samples were HPV low risk
single HPV 53 (3.3%) and HPV 54 (3.3%). Single
HPV 58 infection was 12.5% found in CIN 3.
This study was almost in line with the cohort
study conducted by Siddiqa A., et al in Pakistan. In
the samples of cervical cancer co-infection of HPV
16 and 18 was 34.88%, while a single infection by
HPV 16 and HPV 18 were 27.91% and 30.23%,
respectively. In high degree lesions (CIN 2 and 3)
single infection of HPV 16 and HPV 18 respectively
was 18.18%, while the co-infection of HPV 16 and
18 was found 54.54%.30
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Differences in the prevalence of HPV can be
caused by several factors, including the sensitivity
of PCR (primary election: MY09 / MY11 versus GP
5 + / 6 +), the quality of the specimen and spe-
cimen storage. Thus, the extent of variability that
exists is difficult to compare the prevalence of HPV
among research.33
HPV DNA methylation is a promising biomarker
for diagnosis and prognosis of cervical cancer. After
HPV DNA genotyping, 50 samples with either
single or multiple infection (co-infection) of HPV
16 and 18 were preceded to the examination
methylation. Samples with co-infection of HPV 16
and 18 were examined in a both the group of HPV
single infection using primers specific for HPV 16
and also with the single HPV 18 group using
primers specific for HPV 18.
The bisulfite conversion procedures uses the EZ
DNA methylation Kit reagen, Cat No. D5001
Lot.ZRC186674 (Zymo Research Corp., CA, USA).
After the bisulfite conversion procedure, PCR
procedure was then performed. Primers used for
this procedure were HPV16 FP, RP HPV16, HPV18
and HPV18 FP RP, Integrated DNA Technology.20-22
After several stages of optimization, we obtained
a thin band on 8 samples (19%) HPV 16 but were
polluted with dimers. Purification of the samples
was then performed. On the electrophoresis
reading after the PCR examination of the purified
samples there were no band visible. This is likely
due to small amount of DNA yield. It can also occur
because the samples have been through the stages
of bisulfite treatment that alter the components
cytosintothiamine, which has a lower binding
affinity. HPV detection methods on the tissue
samples that have been processed with paraffin are
more difficult to examine compared to the citology
specimens. This can be caused by formalin fixation
can cause DNA damage, including cross-linking and
fragmentation.23
As in the case of genotyping procedures that
needed several stage of optimization, HPV DNA
methylation procedures also needs some optimi-
zation. We plan to add the volume of templates and
make modifications to the protocol procedures as
a part of optimization to achieve valid results.
Until now, the optimization process for HPV
DNA methylation is still carried out and therefore
we can not take final conclusion.
CONCLUSION
HPV 16 infection were most commonly found in
the form of single or multiple. Co-infection of HPV
16 and 18 were found in the majority of the
samples. There were no significant correlation
between HPV type and the severity of cervical
lesions. We already obtained eight samples of HPV
16 with a thin band on electrophoresis, however
the result could not be concluded because the
optimization is still ongoing.
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